Skip to main content
. 2017 May 18;8(6):1573–1586. doi: 10.1016/j.stemcr.2017.04.019

Figure 1.

Figure 1

Differentiation Capacity of BM-MSCs from HDs and AML Patients

(A) Phase-contrast morphology of BM-MSCs from HD and AML patients.

(B) Top: oil red O staining indicative of adipogenic differentiation potential of BM-MSCs from HD, LR-, IR-, and HR-AML subjects. Bottom: quantitative expression by qRT-PCR for the pan-adipogenesis transcription factors cEBPa and PPAR.

(C) Top: alizarin red staining revealing the osteogenic differentiation capacity of BM-MSCs from HD, LR-, IR-, and HR-AML subjects. Bottom: quantitative expression by qRT-PCR for the pan-osteogenesis transcription factors ALPL, OSTERIX, and OSTEOPONTIN. Original magnification is indicated in microscopy images. n = 30 patients (10 LR-, 10 IR-, and 10 HR-AML) and n = 10 healthy donor controls.

Error bars indicate the SEM values of the biological replicates. ∗p < 0.05.